Details

Project TitleMETHOD FOR DETECTING AND TREATING NASAL AND LUNG DYSBIOSIS PATIENTS WITH MICROORGANISMS
Track Code28797
Websitehttps://techtransfer.universityofcalifornia.edu/NCD/28797.html?utm_source=AUTMGTP&utm_medium=webpage&utm_term=ncdid_28797&utm_campaign=TechWebsites
Short Description

Researchers at the University of California, San Francisco have demonstrated that distinct populations of microbiota in patients with acute infection or chronic inflammatory disease are associated with distinct immune dysfunction and differences in clinical response. They have developed a method to obtain a microorganism sample and probe the microorganism population to identify diversity and plurality of microbiota. 

Abstract

This invention uses sequencing of microbiota community for diagnosis and treatment of lung and nasal dysbiosis.

 
Tagsmicroorganisms, Nasal dysbiosis, Lung dysbiosis, Respiratory System, Immune dysfunction, Inflammatory disease, health, Diagnostics, Disease: Respiratory and Pulmonary System, Therapeutics
 
Posted DateJul 25, 2017 7:53 AM

Advantages

The respiratory system hosts a large and diverse number of microorganisms, which function as a unit and are associated with human health and disease states. Distinct compositions of microbiota are associated with the development of distinct immune dysfunctions, including inflammatory bowel disease, pediatric asthma, acute pneumonia and chronic rhinosinusitus, and are also associated with significant differences in clinical outcomes. Currently, microbiota are not considered during diagnosis of lung or nasal dysbiosis. This invention identifies microbial endotypes that would benefit from differentiated therapy. 

This novel invention provides the following benefits:

-Rapid access to testing results

-Relatively inexpensive testing

-Opportunity to implement precision medicine   

Potential Applications

-Identify distinct populations of microbiota in patients

-Develop tailored treatment based on microbiota composition

Additional Information

Stage of Development

Preclinical



Looking for Partners

To develop and commercialize this technology to stratify and treat nasal and lung dysbiosis patients



Data Availability

Under NDA/CDA

Inventors Profile

Susan Lynch, PhD http://profiles.ucsf.edu/susan.lynch  

 



Tech ID/UC Case

28797/2017-187-0



Related Cases

2017-187-0

Contact Information

Name : Lindsay Sanford

Title :

Department :

Email : Lindsay.Sanford@ucsf.edu

Phone :

Address :

Principal Investigator

Name : Susan Lynch

Department :

Intellectual Property

Patent Number : 20200332344

Patent Title :

Patent Application Date :

Patent Publication Date :

Patent Issue Date : Oct 22, 2020

Patent Link : http://www.google.com/patents/US20200332344